All In Biotech

Drug Trial Radar · NCT05265273

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 20, 2022

Primary completion

Jun 30, 2027

Study completion Jul 2, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.

Conditions

  • Myasthenia Gravis

Interventions

  • NipocalimabDrug

    Nipocalimab will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Serum Immunoglobulin-G (IgG) LevelsTime frame: Up to 3 years
  2. Number of Participants with Infectious Adverse Events (AEs)Time frame: Up to 3 years
  3. Number of Participants with Serious AEs (SAEs)Time frame: Up to 3 years
  4. Number of Participants with Adverse Events of Special Interests (AESIs)Time frame: Up to 3 years
  5. Number of Participants with Abnormalities in Clinical Laboratory TestsTime frame: Up to 3 years
  6. Number of Participants with Abnormalities in Vital SignsTime frame: Up to 3 years
  7. Number of Participants with Abnormalities in Physical ExaminationTime frame: Up to 3 years
  8. Serum Concentration of Nipocalimab over TimeTime frame: Up to 3 years
  9. Clearance (CL) of NipocalimabTime frame: Up to 3 years
  10. Volume of Distribution (V) of NipocalimabTime frame: Up to 3 years
  11. Half-life (t1/2) of NipocalimabTime frame: Up to 3 years
  12. Steady-state Peak Concentration (Cpeak,ss) of NipocalimabTime frame: Up to 3 years
  13. Steady-state Trough concentration (Ctrough,ss) of NipocalimabTime frame: Up to 3 years
  14. Steady-state Area Under the Curve (AUCss) of NipocalimabTime frame: Up to 3 years

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Childrens Hospital Los Angeles

    Los Angeles, California · Completed

  • Lucile Packard Children's Hospital Stanford

    Palo Alto, California · Recruiting

  • UCSF Benioff Children's Hospital

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • University of South Florida Morsani Center for Advanced Healthcare

    Tampa, Florida · Recruiting

  • University of Kansas Medical Center

    Lawrence, Kansas · Completed

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • Penn State Milton S Hershey Medical Ctr

    Hershey, Pennsylvania · Recruiting

  • Childrens Hospital Of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Terminated

  • Nagano Children's Hospital

    Azumino-shi, Japan · Recruiting

  • Chiba University Hospital

    Chiba, Japan · Completed

  • University of Miyazaki Hospital

    Miyazaki, Japan · Recruiting

  • Hyogo College of Medicine Hospital

    Nishinomiya-Shi, Japan · Recruiting

  • Saitama Prefecture Children's Medical Center

    Saitama Shi, Japan · Recruiting

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Japan · Recruiting

  • Leiden University Medical Center

    Leiden, Netherlands · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.